(Q46262776)

20 December 2017

title

The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride (English)

1 reference

20 December 2017

author

Konstantinos Stamatiou

1

1 reference

20 December 2017

author name string

Paraskevi Zaglavira

2

1 reference

20 December 2017

Andrew Skolarikos

3

1 reference

20 December 2017

Frank Sofras

4

1 reference

20 December 2017

publication date

1 September 2008

1 reference

20 December 2017

International Brazilian Journal of Urology

published in

1 reference

20 December 2017

volume

34

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

555-61; discussion 561-2

1 reference

20 December 2017

Benign prostatic hyperplasia: age-related tissue-remodeling

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Benign Prostatic Hyperplasia: Antecedents and Natural History

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

The role of dihydrotestosterone in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Correlations between hormones, physical, and affective parameters in aging urologic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Statins and prostate cancer prevention: where we are now, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Do the cholesterol-lowering properties of statins affect cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382008000500003

10.1590/S1677-55382008000500003

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017